-
Mashup Score: 1Survival in Patients With Hematologic Cancers and COVID-19 - 8 month(s) ago
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Patients with plateau-phase multiple myeloma have an increased risk of life-threatening bacterial infections and polyclonal humoral immune suppression. We conducted a randomised, double-blind, placebo-controlled, multicentre trial of intravenous immunoglobulin (IVIg) as prophylaxis against infection …
Source: pubmed.ncbi.nlm.nih.govCategories: Hem/Oncs, Latest HeadlinesTweet-
RCT of IVIg as Px vs infection in plateau-phase myeloma [1994] Chapel et al. @thelancet https://t.co/6wbQlr2IpO #mmsm #IDonc - 57% PV response
-
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 8 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx
-
-
Mashup Score: 0Vaccination in Multiple Myeloma: Review of Current Literature - 8 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc
-
-
Mashup Score: 1Multiple Myeloma Baseline Immunoglobulin G Level and Pneumococcal Vaccination Antibody Response - 8 month(s) ago
Infections are a major cause of morbidity and mortality in multiple myeloma (MM), a cancer of the immune system. Vaccination clinical efficacy endpoints have not been demonstrated, and there are limited data on surrogate markers of efficacy. This pilot study evaluated sequential immunologic markers after standard pneumococcal vaccination (PV) in patients with MM and non-MM controls. Vaccination was standard for PV (PCV13 or PPV23), with laboratory testing at baseline and at 2, 4, 12 and 24 weeks after vaccination. Immunoglobulin G (IgG) antibodies to pneumococcal antigens were detected by ELISA. Prevaccination total IgG levels and IgG subclass levels were also measured by ELISA. Four of 6 controls responded with at least a 2-fold increase in antibody concentration; only 2 controls had a sustained increase in concentration. Six of 8 patients with MM had at least a 2-fold antibody increase; however, only 2 of these patients showed a sustained increase of antipneumococcal antibody. Respon
Source: institutionalrepository.aah.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Multiple Myeloma IgG Level & Pneumococcal Vaccination Ab Response [Aug 10, 2017] @mtmdphd et al. @JPCRR https://t.co/x5dZNhopn5 #mmsm #ImmunoOnc #IDonc https://t.co/FbGhCurz8b
-
-
Mashup Score: 0
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Prevention of infections including vaccination strategies in multiple myeloma [Oct 17, 2022] Ludwig & @myelomaMD https://t.co/t6hCCDoY1i #mmsm #IDonc
-
-
Mashup Score: 0Recommendations on prevention of infections during chimeric antigen receptor T‐cell and bispecific antibody therapy in multiple myeloma - 8 month(s) ago
An official journal of the British Society for Haematology, the British Journal of Haematology offers high visibility for clinical, basic and translational research.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Recs on prevention of infections during #CARTcell & bispecific antibody Tx in myeloma [6/7/23] @MeeraMohanMD @rajshekharucms @SusanBal9 Nellore @MMBaljevicMD @adsouza_md @DrPappasID @BerdejaJesus @nsc_natalie @End_myeloma @BrJHaem https://t.co/Ay6wRTWBXU #mmsm #IDonc
-
-
Mashup Score: 1Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival. - 8 month(s) ago
8016 Background: B cells are critical to inhibiting tumor progression, as they generate tumor-reactive antibodies; promote anti-tumor killing capacity of NK cells and phagocytosis of macrophages/DCs; and enrich priming of T cells against the tumor. Multiple myeloma (MM) is a B-cell-derived malignancy, and its survival is partly driven by a deficiency in the immune response. Yet, the abnormalities of the B-cell-mediated humoral responses in MM are ill defined. Methods: We investigated B cell composition in bone marrow (BM) from patients with newly diagnosed MM (NDMM, N = 170), relapsed refractory MM (RRMM, N = 140) and healthy donors (HD, N = 21) by multi-color flow cytometry. Results: We observed that B1b cells was significantly reduced by 45% (p = 0.004) in NDMM patients compared to HD. B1b cells are important in generating long-lasting protective antibodies, particularly against vaccines, in a T cell independent fashion. Similarly, B2 cells, which can produce all antibody types, were
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival [May 31, 2023] @LBP0818 et al. #ASCO23 Abstract 8016 https://t.co/ncOFXseFoV #mmsm #IDonc #ImmunoOnc cc @DrTJM_MD @BilalAbidMD @DrJPHenderson
-
-
Mashup Score: 0Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients - 8 month(s) ago
The American Journal of Hematology publishes research in blood diseases in humans & animal model, covering all hematological diseases including leukemia, hemostasis and thrombosis.
Source: onlinelibrary.wiley.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Measles, rubella, and mumps titers post chemotherapy plus autologous stem cell transplant in multiple myeloma patients [Nov 25, 2021] Mariano Arribas et al. @Rfonsi1 @AjHematology https://t.co/DHKdQ8mXll #mmsm #bmtsm #IDonc HT @RahulBanerjeeMD
-
-
Mashup Score: 8Vaccination in Multiple Myeloma: Review of Current Literature - 8 month(s) ago
Multiple myeloma is a cancer of the immune system. Infection is a major cause of morbidity and mortality in patients with multiple myeloma. Some of these infections are preventable by vaccines available to the general population. However, little is known about the clinical effectiveness of these vaccines in patients with multiple myeloma, and the cellular and humoral immune response to vaccination has not been well characterized, especially in conjunction with modern myeloma therapies. The present report reviews the basics of multiple myeloma and the immune system, the available evidence on the immunologic response of patients with multiple myeloma after vaccination, and current practice recommendations regarding specific vaccines.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Vaccination in Multiple Myeloma: Review of Current Literature [Jun 8, 2016] Alemu et al. @mtmdphd CLML https://t.co/bhwKr0nDDw #mmsm #ImmunoOnc #IDonc https://t.co/3QZ4zfn8yz
-
Convalescent Plasma and Survival in Hematologic Malignancy and COVID-19 [Jun 17, 2021] @mtmdphd & @DrJPHenderson et al. @jwsenefeld @DrDimpyShah @hemoncwarner @COVID19nCCC - @JAMAOnc https://t.co/g3GP7EsUeS #COVID19CP #CCC19 #COVID19nCancer #COVID19 #IDonc https://t.co/QJjqtd6M2Z